CASP6

Across TCGA pan-cancer cohorts, CASP6 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CASP6 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CASP6 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CASP6 expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where CASP6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	IV	0.381	0.951	.006	13	view →
CCRCC	DFS	Tertile	All	0.675	0.878	.014	12	view →
GBM	OS	Quartile	All	0.729	0.916	.006	6	view →
LUAD	DFS	Tertile	II,III,IV	0.277	0.739	.002	6	view →
UCEC	OS	Median	All	0.984	0.916	.047	4	view →
HNSC	DFS	Median	All	0.861	0.710	.030	3	view →
LSCC	OS	Tertile	All	0.883	0.922	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CASP6–PDAC (OS)

Open the PDAC breakdown →